ALSTON & BIRD LLP for CVS CAREMARK INC (FORMERLY CAREMARK RX INC )
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues relating to comprehensive health care reform, insurance reforms, delivery system, expanding coverage for the uninsured, and increasing health care value. Other specific issues include PBM disclosure requirements, generic drug reimbursement under Medicaid, tax issues, changes to Medicare Part D and prevention & wellness issues. Expanding access to generic drugs and creating an FDA pathway to bring generic versions of biologics to market; realignment of incentives for generic manufacturers to challenge brand patents for earlier market entry. H.R. 3200 Americas Affordable Health Choices Act of 2009 S. 1679 Affordable Health Choices Act Americas Healthy Future Act of 2009 H.R. 1706 - Protecting Consumer Access to Generic Drugs Act of 2009 H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S.726 - Promoting Innovation and Access to Life-Saving Medicine Act S. 1315-Drug Price Competition Act of 2009 H.R. 1548 - Pathway for Biosimilars Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER L BUTLER | — |
| STEPHANIE A KENNAN | — |
| MARK RAYDER | — |
| THOMAS A SCULLY | — |
| TAMARA CARTY TENNEY | — |
| TIMOTHY P TRYSLA | — |
Medicare/Medicaid MMM
Changes to the Medicare and Medicaid programs, including rebate structures and formularies, coverage, pharmacy reimbursement for generic drugs under Medicaid, disclosure of PBM information and the Medicare DME program. H.R. 3200 Americas Affordable Health Choices Act of 2009; Americas Healthy Future Act of 2009; S. 956/H.R. 1970-Preserve Patient Access to Reputable DMEPOS Providers Act of 2009
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER L BUTLER | — |
| MARK RAYDER | — |
| THOMAS A SCULLY | — |
| TAMARA CARTY TENNEY | — |
| TIMOTHY P TRYSLA | — |
Labor Issues/Antitrust/Workplace LBR
Issues related to recommendations for the reauthorization of the WIA including increasing employer involvement and ways to increase the success of these programs. Workforce Investment Act reauthorization. Issues related to potential changes to drug benefits offered under FEHBP.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER L BUTLER | — |
| STEPHANIE A KENNAN | — |
| MARK RAYDER | — |
| THOMAS A SCULLY | — |
| TAMARA CARTY TENNEY | — |
| TIMOTHY P TRYSLA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.